Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

89bio Hopes Akero’s Success In Cirrhotic NASH Is Positive For FGF21 Class

Mar 24 2021

• By Joseph Haas

Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost. — 89bio has a plan to compete in NASH and the FGF21 analog space

Related Content

NASH Drug Development Questions? US FDA Has Many Of The Answers

Feb 12 2021

Stealthy NGM And Bristol Emerge As Serious NASH Competitors

Apr 25 2017

Year Of NASH Upheaval Means Incremental Data At AASLD

Nov 18 2020

No Read-Through Expected: NASH Field Unfazed By Intercept’s FDA Rejection

Jul 03 2020

Akero First To Show Benefit In Cirrhotic NASH Patients

Mar 23 2021

89Bio’s NASH Hopes Hang On Demonstrating Best-In-Class FGF21 Profile

Feb 11 2020

Akero Looks To Accelerate Path To Pivotal NASH Data With Phase IIb/III Protocol

Sep 24 2020

Related Companies

89bio, Inc.

Akero Therapeutics, Inc.

Bristol Myers Squibb Company

Genfit SA

Intercept Pharmaceuticals, Inc.

Additional Topics

Clinical Trials Business Strategies Drug Approval Standards Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window